New 1-phenylmethyl benzimidazole piperazine derivatives

Abstract: New 1-phenylmethyl benzimidazole piperazine derivatives of general formula are described wherein R¹ and R² can be a hydrogen atom, a halogen atom, a short chain alkyl group, a nitro group, and a hydroxy group, and their addition salts with pharmaceutically acceptable acids. These compounds have pharmacological activity as serotonin 5HT₃ receptor antagonists.

Description: The present invention relates to new 1-phenylmethylbenzimidazole piperazine derivatives, a process for preparing the same and their addition salts with pharmaceutically acceptable acids. In particular, new compounds of formula (I) are described wherein R 1 can be a halogen atom, a short chain alkyl group, nitro and hydroxy, and R 2 can be a hydrogen atom, a halogen atom, a short chain alkyl group, a nitro group, and a hydroxy group. The short chain refers to a 1 to 3 carbon atom radical, linear or branched, the halogen atoms can be Cl, Br, F or I. This invention similarly comprises the addition salts of these compounds with inorganic acids such as hydrochloric, hydrobromic, phosphoric and sulphuric acids, and organic acids such as acetic, fumaric, tartaric, oxalic and benzoic acids. Certain benzimidazole derivatives containing piperazine at position 2 in the benzimidazole are known which structurally resemble the compounds of the present invention. Thus, US Patent 4,093,726 describes compounds of formula (A) with hypotensive activity: wherein R is an H atom or a methyl group; R' is an alkyl group, an acyl group, an aryl group, an alkoxy carbonyl group, a tetrahydrofuroyl group, a dialkyl aminocarbonyl group or a furoyl group; R'' is a hydrogen atom or a methoxy group. Similarly, patent EP 0,079,545 describes benzimidazole piperazines with antihistaminic activity of general formula (B) wherein R'' is hydrogen or a short chain alkyl group and R' is a short chain alkyl group, an allyl group, a propargyl group or a phenyl group. Though structurally akin, the foregoing compounds differ from the compounds of the present invention in that the substituent at N 1 in benzimidazole is the phenylmethyl group in all cases. The compounds of the present invention are moreover always free piperazines, viz. piperazine is never substituted other than by a hydrogen atom at position 4 . Both of these facts are very significant from the standpoint of 5HT 3 antagonist activity of the new derivatives described in the present invention. The document EP-A 0 512 939 discloses 1-phenylmethyl 2-piperazinyl benzimidazol derivatives having the above formula (I), wherein the R 1 and R 2 substituents are simultaneously hydrogen, i. e. wherein the phenylene residue bears no substituent. The process for preparing the said compounds basically comprises reacting a halogenated derivative of general formula (II) wherein R 1 can be a halogen atom, a short chain alkyl group, nitro and hydroxy, and R 2 can be hydrogen, a short chain alkyl group, a halogen atom, a nitro group and a hydroxy group, and wherein X is a halogen, preferably chlorine, with piperazine. Reaction takes place mixing equimolar quantities of the reagents admitting a piperazine surplus of up to 5 to 1 over the halogenated derivative (II) and heating the reaction mixture to 80-100°C for a time interval ranging between five and thirty minutes. The invention also relates to the above new 1-phenylmethyl benzimidazole piperazine derivatives of the general formula (I) for use in the medical field. The invention also relates to the above new 1-phenylmethyl benzimidazole piperazine derivatives of the general formula (I) for use as serotonin 5HT 3 receptor antagonists. The invention also relates to the above new 1-phenylmethyl benzimidazole piperazine derivatives of the general formula (I) for use in the prevention of vomit induced by anticancerous agents. The invention also relates to the above new 1-phenylmethyl benzimidazole piperazine derivatives of the general formula (I) for use in the prophylaxis and treatment of migraine, anxiety and neuralgic disorders. The invention also relates to pharmaceutical preparations comprising at least one of the above new 1-phenylmethyl benzimidazole piperazine derivatives of the general formula (I) in pharmaceutically effective amounts, together with usual carriers, excipients and diluents. The pharmacological activities of the compounds referred to in this invention were revealed in tests with animals using well established pharmacological processes. Three of the tests made are cited for illustrative purposes and the results set down in Table I. a) Male and female Wistar rats weighing 180-220 g were anaesthetised with urethane (1.25 g/kg i.p.) and then submitted to cannulation of the trachea, carotid artery and jugular vein, with spontaneous breathing and at a rectal temperature of 37-38°C. After the arterial pressure (A.P.) and cardiac frequency (C.F.) parameters were stabilised, bradycardia reflex was induced by i.v. injection (the different doses of the drug tested) of 80 µv/kg (1 ml/kg) of serotonin dissolved in sterile physiological serum. Ten minutes later and after taking CF and AP back to constant levels, the products claimed herein were injected i.v. and after a lapse of five minutes, i.v. injection of the serotonin creatinine sulphate complex was repeated, quantifying the inhibition of the Bezold-Jarisch reflex. All the compounds tested displayed activity between 0.3 and 10 µg/kg revealing themselves therefore as serotonin 5HT 3 receptor antagonists. b) Guinea pig ileum fragments were submerged in K-H solution at 37°C, pH 7.4, oxygenated with carbogen (95% O 2 and 5% CO 2 ) and with an effective preload of 1-2 g. They remained in a stabilization period for 45-60 minutes and the physiological solution was replaced every 15 minutes. After this time, contractions were induced every 15 minutes, adding 2-methyl-serotonin (final conc.: 10 µmol/l). When contraction intensity was found to be even, the products being tested were added at different concentrations and after incubation for 15 minutes contraction induced by the 5HT 3 antagonist, 2-methyl serotonin, took place again. The inhibition percentages and CI50 were subsequently calculated (Table I). c) The inhibition of vomit induced by cis-platinum in a conscious dog was studied. The products were administered intravenously 30 minutes before and 2 hours after cis-platinum (3 mg/kg i.v., 1 ml/kg). A record was made of the number of emetic episodes occurring for five hours after cis-platinum was administered. The products of the present invention were more active than ondansetron in preventing cis-platinum induced vomit. The results of all the tests show that the compounds of the invention antagonise the action of serotonin at the 5HT 3 receptor level and are hence suitable for preventing vomit induced by anticancerous agents, such as cis-platinum and radiations, and are potentially useful in prophylaxis and treatment of migraine, anxiety and other neuralgic disorders. The following example provides further details on the invention without in any way limiting the same. Example 1 Preparing 5-fluoro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole 25 mmoles (2.15 g) of piperazine were added to 5 nmoles (1.4 g) of 2-chloro-5-fluoro-1-phenylmethyl benzimidazole and the mixture heated until both solids fused together, keeping the heat and stirring for 20 minutes. After this time, the reaction mixture was poured onto 100 ml of H 2 O, 10% NaOH added, and it was extracted with CH 2 Cl 2 (2 x 100 ml), the organic phase being dried on anhydrous Na 2 SO 4 and concentrated at reduced pressure. The oil obtained was purified by flash chromatography using MeOH/CH 2 Cl 2 : 1/9 as eluant to obtain 1 g of oil which upon being washed with Hexane/ether precipitated as a cream-coloured solid (0.5 g 1.6 mmoles 32% yield) melting at 67-65°C, its 1 H and 13 C NMR and the IR spectroscopic data confirming the structure of the product: 5-fluoro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. The following were prepared in like wise: 5-chloro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. Melting point 114-116°C. 5-hydroxy-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. Melting point 100-102°C. 5-methyl-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. Melting point 106-108°C. 5,6-dichloro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. Melting point 160-2°C. 5-nitro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole fumarate. Melting point decom >200°C.

Claims: 1-Phenylmethyl benzimidazole piperazine derivatives having the general formula (I) wherein R 1 represents a halogen atom, a 1 to 3 carbon atom linear or branched alkyl group, a nitro group or a hydroxy group and R 2 represents a hydrogen atom, a halogen atom, a 1 to 3 carbon atom linear or branched alkyl group, a nitro group or a hydroxy group, and their addition salts with pharmaceutically acceptable acids. 1-Phenylmethyl benzimidazole piperazine derivatives according to claim 1 wherein the derivatives are 5-methyl-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. 5-chloro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. 5-nitro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. 5-fluoro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. 5-hydroxy-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. 5,6-dichloro-1-phenylmethyl-2-piperazinyl-1H-benzimidazole. Process for preparing 1-phenylmethyl benzimidazole piperazine derivatives having the general formula (I) according to claim 1 by reacting 1-phenylmethyl benzimidazole derivatives having the general formula (II), wherein R 1 and R 2 are defined as in claim 1 and X represents a halogen atom, with piperazine at elevated temperatures. The process according to claim 3 wherein the reaction is carried out at a temperature in the range of from 80 to 150 °C. The process according to claims 3 and 4 wherein the reaction is carried out within a time period of from 5 to 30 minutes. The process according to any of claims 3 to 5 wherein piperazine is employed in an amount up to 5 to 1 over the derivatives of the general formula (II). The compounds of the general formula (I) as defined in claim 1 for use in the medical field. The compounds of the general formula (I) as defined in claim 1 for use as serotonin 5HT 3 receptor antagonists. The compounds of the general formula (I) as defined in claim 1 for use in the prevention of vomit induced by anticancerous agents. The compounds of the general formula (I) as defined in claim 1 for use in the prophylaxis and treatment of migraine, anxiety and neuralgic disorders. Pharmaceutical preparations comprising at least one of the compounds of claim 1 in pharmaceutically effective amounts, together with usual carriers, excipients and diluents.

Inventors: ORJAVES-VENERO AURELIO, RODES-SOLANES ROSA, ORJAVES-VENERO, AURELIO, RODES-SOLANES, ROSA
Applicants: ESPANOLA DE PRODUCTOS FAB, FABRICA ESPANOLA DE PRODUCTOS
Application year: 1994
Main classification: C07D235
IPC codes: C07D235